(Press-News.org) BOSTON (June 8, 2015) -- One member of a widely prescribed class of drugs used to lower blood glucose levels in people with diabetes has a neutral effect on heart failure and other cardiovascular problems, according to the first clinical trial to examine cardiovascular safety in a GLP-1 receptor agonist, presented at the American Diabetes Association's 75th Scientific Sessions.
The Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) study also found a modest benefit for weight control, and no increase of risk for hypoglycemia or pancreatic injury in those who took lixisenatide, one of several GLP-1 receptor agonists being prescribed around the world to treat people with type 2 diabetes. GLP-1 receptor agonists are derived from gut hormones and may be used as a secondary therapy when other medications fail to sufficiently lower blood glucose levels.
"There has been a cloud of suspicion over all new diabetes drugs, including GLP-1 agonists, over whether they may increase the risk for cardiovascular problems," said Marc Pfeffer, MD, PhD, Dzau Professor of Medicine at Harvard Medical, Senior Physician in Cardiology at Brigham and Women's Hospital and Principal Investigator for the ELIXA trial. "There has also been some hope that some of these drugs may improve cardiovascular health. GLP-1 receptor agonists were being used around the world while CVD safety had yet to be established. This is the first report of a clinical trial designed to assess cardiovascular outcomes in this class of drugs and we have shown that patients and their healthcare providers should have no cause for concern, even if they are at high risk for heart-related problems."
Specifically, the ELIXA study found no increased risk for cardiovascular death, heart attack, stroke, unstable angina (chest pain) or heart failure in people with type 2 diabetes who had recently experienced acute coronary syndrome events (an umbrella term referring to when blood supplied to the heart muscle is suddenly blocked) and were therefore at high risk for additional heart problems. The study examined 6,068 people from 49 countries, randomly assigning them to lixisenatide or placebo, with a follow-up period of more than two years.
Heart disease and stroke are the number one causes of death and disability among people with type 2 diabetes, who are two to four times more likely than those who do not have diabetes to suffer from these conditions. Because of this, the U.S. Food and Drug Administration has recently augmented cardiovascular surveillance for new drugs prescribed to treat elevated blood glucose in patients with type 2 diabetes, including GLP-1 receptor agonists.
The ELIXA trial also showed that those who took lixisenatide were not more likely to have problems with hypoglycemia (low blood glucose) than those who took placebo, despite better blood glucose control.
"Knowing these drugs can be prescribed safely gives physicians another tool to further lower glucose without producing more hypoglycemia, a potential complication of improved glycemic control," said Eldrin Lewis, MD MPH, Associate Professor of Medicine, Harvard Medical School, Advanced Heart Disease section of Cardiovascular Division at Brigham and Women's Hospital. "These drugs can provide a very important adjunct to therapy. We want to get people to target to minimize the future consequences of diabetes, but we don't want to add any additional risks in doing so."
The ELIXA trial also found no increase in pancreatitis or cancers and a modest benefit in terms of weight gain, said Matthew Riddle, MD, Professor of Medicine, in the Division of Endocrinology, Diabetes, & Clinical Nutrition, at Oregon Health & Science University. Those taking lixisenatide did not gain weight, while those taking placebo did.
Those taking lixisenatide did, however, report a higher number of episodes of nausea and vomiting, common side effects for GLP-1 receptor agonists. "Nausea and vomiting sometimes caused patients to discontinue the medication," said Riddle, "but in terms of serious reactions or pancreatic problems, there was no difference between the two groups and no increased risk."
Dr. Pfeffer will lead a symposium on The Evaluation of Lixisenatide in Acute Coronary Syndrome -- The Results of ELIXA on Monday, June 8 from 2:15 - 4:15 p.m. The ELIXA results will be followed by results from another cardiovascular safety trial, Results from the Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin (TECOS) from 4:30 - 6:30 p.m.
INFORMATION:
The American Diabetes Association is leading the fight to Stop Diabetes® and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. For the past 75 years, our mission has been to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (800-342-2383) or visit diabetes.org. Information from both these sources is available in English and Spanish.
A team of researchers from UC San Diego, Florida State University and Pacific Northwest National Laboratories has for the first time visualized the growth of 'nanoscale' chemical complexes in real time, demonstrating that processes in liquids at the scale of one-billionth of a meter can be documented as they happen.
The achievement, which will make possible many future advances in nanotechnology, is detailed in a paper published online today in the Journal of the American Chemical Society. Chemists and material scientists will be able to use this new development in their ...
ALMA's Long Baseline Campaign has produced a spectacularly detailed image of a distant galaxy being gravitationally lensed. The image shows a magnified view of the galaxy's star-forming regions, the likes of which have never been seen before at this level of detail in a galaxy so remote. The new observations are far more detailed than those made using the NASA/ESA Hubble Space Telescope, and reveal star-forming clumps in the galaxy equivalent to giant versions of the Orion Nebula.
ALMA's Long Baseline Campaign has produced some amazing observations, and gathered unprecedentedly ...
An international, multidisciplinary team including investigators from Brigham and Women's Hospital (BWH) has found that lixisenatide, a member of a class of glucose-lowering drugs frequently prescribed in Europe to patients with diabetes, did not increase risk of cardiovascular events including heart failure. These results - the first to be reported on the cardiovascular safety of a glucagon-like peptide 1 (GLP-1) receptor agonist - were presented today at the American Diabetes Association's 75th Scientific Sessions.
"There are a large number of patients around the world ...
ORANGE, Calif. -- In a study just published by researchers at Chapman University, findings showed that greater life satisfaction in adults older than 50 years of age is related to a reduced risk of mortality. The researchers also found that variability in life satisfaction across time increases risk of mortality, but only among less satisfied people. The study involved nearly 4,500 participants who were followed for up to nine years.
'Although life satisfaction is typically considered relatively consistent across time, it may change in response to life circumstances ...
Glenview, Ill. (June 8, 2015)-- A Canadian study published in the June issue of the journal CHEST found weight loss reduced asthma severity as measured by airway hyperresponsiveness (AHR) in obese adults. The incidence of asthma is 1.47 times higher in obese people than nonobese people, and a three-unit increase in body mass index is associated with a 35% increase in the risk of asthma. The study supports the active treatment of comorbid obesity in individuals with asthma.
The study, the first of its kind to rely on appropriate physiologic tests as diagnostic criteria ...
Baltimore, Md. (Embargoed until 12:30 p.m. EDT, June 8, 2015) - Imaging lung cancer requires both precision and innovation. With this aim, researchers have developed a technique for clinical positron emission tomography (PET) imaging that creates advanced whole-body parametric maps, which allow quantitative evaluation of tumors and metastases throughout the body, according to research announced at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
Scientists have developed a novel agent for cancer imaging that seeks and attaches ...
Baltimore, Md. (Embargoed until 12:30 p.m. EDT, June 8, 2015) - A first-in-human study revealed at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) shows how a powerful new drug finds and attaches itself to the ovarian and prostate cancer cells for both imaging and personalized cancer treatment.
The targeted aspect of the imaging agent, called I-124 PEG-AVP0458, is a small protein (avibody) linked to polyethylene glycol (PEG) chains. The drug compound is then labeled with the radionuclide iodine-124. Drugs like PEG-AVP0458 are ...
Baltimore, Md. (Embargoed until 12:30 p.m. EDT, June 8, 2015) - Non-Hodgkin lymphoma (NHL), a potentially devastating cancer of the blood and immune system, can range from relatively easy to treat to very aggressive. For more aggressive cases, post-treatment surveillance with molecular imaging could mean the early start of a new, life-saving treatment, say researchers presenting during the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
NHL is the fifth most prevalent cancer in America, according to lead author Mehdi Taghipour, MD, ...
Baltimore, Md. (embargoed until 12:30 p.m. EDT, June 8, 2015) - Research presented at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) shows how a new molecular imaging agent finds prostate cancer that has spread to other tissues by locking in on an enzyme called prostate specific membrane antigen (PSMA), associated with prostate cancer.
"To date, conventional imaging is limited in detecting prostate cancer metastasis accurately and measurably," said Neeta Pandit-Taskar, MD, co-author of the study and a researcher at Memorial Sloan ...
A recently developed tool can accurately predict the risk of death for patients within 1 year after admission to hospital using routinely collected data, reports a study in CMAJ (Canadian Medical Association Journal).
"An accurate assessment of risk of death, particularly if that risk is high, could motivate and inform discussions between patients and physicians regarding goals of care," states Dr. Carl van Walraven, a researcher at the Ottawa Hospital and the University of Ottawa, Ottawa, Ontario, who developed the tool.
Researchers in Canada and the United States ...
